PrimeRFP SCOUT · Federal Contract Recompete Brief

36C25023D0021Radiopharmaceutical DRUGS EO 14398 — Schaaf Drugs, LLC

Schaaf Drugs, LLC holds $3.7M across 18 federal awards, concentrated at Department of Veterans Affairs (VA). This PIID sits alongside 5 related awards in the incumbent pipeline. Set-aside status: Unrestricted.

250-Network Contract Office 10 (36C250)

Awarding office

Schaaf Drugs, LLC

Recipient

—

Estimated value

6505

PSC

Unrestricted

Set-aside

Watch this recompete

One email. No account. We ping you if the window moves.

Contract facts

Unrestricted

Contract number36C25023D0021

Also listed as36C250-23-D-0021

Agency250-Network Contract Office 10 (36C250)

Awarding office250-Network Contract Office 10 (36C250)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentSchaaf Drugs, LLC

UEILSEHGNVLAVX5

PSC6505

RADIOPHARMACEUTICAL DRUGS EO 14398 is a federal Unrestricted award for 250-Network Contract Office 10 (36C250) held by Schaaf Drugs, LLC. Estimated value —.

Bonuses end Sept 30

Want the durability read on 36C25023D0021? One Pursuit Analysis, $500, inside 48 business hours.

48 business hours
$500
Credits toward the Pack

Buy one Pursuit Analysis — $500

Incumbent footprint

Public record

Schaaf Drugs, LLC — $3.7M obligated across 18 awards (firm-wide, all agencies).

Sole agency: Department of Veterans Affairs (VA)

Department of Veterans Affairs (VA)$3.7M · 100% of firm total

Open full company profile →

Related awards

Same incumbent

36C25026N0181

YEAR 4, OPTION YEAR 3 PATIENT RADIOPHARMACEUTICAL DRUGS (12 MONTHS)

$681K

Nov 22, 2026

36C25023N0185

RADIOPHARMACEUTICAL DRUGS

$588K

Nov 22, 2027

36C25025N0283

EXERCISING OPTION YEAR 2 01/06/2024 - 01/05/2025

$351K

Jan 5, 2028

36C25026N0185

OY3 (PYP-TC99M ATRIAL AMYLOIDOSIS) CANNOT BE LOCATED ON THE PRICE SCHEDULE FOUND THAT THI…

$351K

Jan 5, 2028

36C25026N0022

EXERCISING FINAL OY

$3.9M

Sep 30, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C25023D0021?

36C25023D0021 (Radiopharmaceutical DRUGS EO 14398) is a 250-Network Contract Office 10 (36C250) award with an estimated value of —, currently held by Schaaf Drugs, LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C250-23-D-0021?

36C250-23-D-0021 is the dashed form of PIID 36C25023D0021 (Radiopharmaceutical DRUGS EO 14398), held by Schaaf Drugs, LLC. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C25023D0021?

250-Network Contract Office 10 (36C250) awarded 36C25023D0021 to Schaaf Drugs, LLC.

Who is the incumbent on 36C25023D0021?

Schaaf Drugs, LLC is the incumbent with $3.7M across 18 related awards in SCOUT’s public footprint.

When does Schaaf Drugs, LLC’s 36C25023D0021 come up for recompete?

SCOUT tracks a period-of-performance end of an unstated date. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Want the durability read on 36C25023D0021? One Pursuit Analysis, $500, inside 48 business hours.

One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.

Get the free Exposure Check

No card · under a minute · then the Sprint menu

Buy one Pursuit Analysis — $500

Credits toward the Sprint Pack

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Jun 25, 2026 · refreshed monthly